Form D · Biotechnology
Sunflower Therapeutics, PBC
Hingham, MA · CIK 0001950773
Offering snapshot reported May 24, 2024 · SEC filing
- Reported sold
- $2.03M Offering amount: $3M
- Investors reported
- 2 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- May 13, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| May 24, 2024 | Initial | $2,030,000 | No comparison | 2 | SEC filing |
| Oct 14, 2022 | Initial | $610,000 | No comparison | 8 | SEC filing |
Offering details
- Securities
- Option to acquire, Security to be acquired, Other
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-514263
Simple agreement for future equity
Source: Form D, filed May 24, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Kathryn Golden | Director |
| Maik Jornitz | Director |
| Kerry R. Love | Director, Executive |
| J. Christopher Love | Director |
| Larry Weiner | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
18 Shipyard Dr., Ste. 2 A
Hingham, MA, 02043
Hingham, MA, 02043